These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30612635)

  • 21. Risk of endometrial carcinoma associated with BRCA mutation.
    Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
    Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
    Ferguson SE; Aronson M; Pollett A; Eiriksson LR; Oza AM; Gallinger S; Lerner-Ellis J; Alvandi Z; Bernardini MQ; MacKay HJ; Mojtahedi G; Tone AA; Massey C; Clarke BA
    Cancer; 2014 Dec; 120(24):3932-9. PubMed ID: 25081409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.
    Barak F; Milgrom R; Laitman Y; Gemer O; Rabinovich A; Piura B; Anteby E; Baruch GB; Korach J; Friedman E
    Gynecol Oncol; 2010 Dec; 119(3):511-5. PubMed ID: 20850175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
    Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lynch Syndrome Identification in Saudi Cohort of Endometrial Cancer Patients Screened by Universal Approach.
    Bu R; Siraj AK; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Alobaisi K; Annaiyappanaidu P; Siraj N; AlHusaini H; Alomar O; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.
    Saule C; Mouret-Fourme E; Briaux A; Becette V; Rouzier R; Houdayer C; Stoppa-Lyonnet D
    J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28954295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.
    Lehrer S; Rheinstein PH
    Am J Clin Oncol; 2021 Jul; 44(7):299-300. PubMed ID: 34008499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.
    Kunnackal John G; Das Villgran V; Caufield-Noll C; Giardiello FM
    Fam Cancer; 2022 Jan; 21(1):57-67. PubMed ID: 33426601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
    J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
    J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    Levine MD; Barrington DA; Hampel H; Goodfellow PJ; Cohn DE
    Gynecol Oncol; 2022 Sep; 166(3):538-542. PubMed ID: 35871048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    Reitsma W; Mourits MJ; de Bock GH; Hollema H
    Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm
    Mannucci A; Furniss CS; Ukaegbu C; Horiguchi M; Fehlmann T; Uno H; Yurgelun MB; Syngal S
    J Clin Oncol; 2020 Dec; 38(34):4086-4094. PubMed ID: 32997573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
    Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
    Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.